Phase II Trial of Metronomic Capecitabine and Cyclophosphamide With Lapatinib and Trastuzumab in Patients With HER2 Positive Metastatic Breast Cancer Who Have Progressed on a Previous Trastuzumab-Based Regimen
Latest Information Update: 09 Oct 2023
At a glance
- Drugs Capecitabine (Primary) ; Cyclophosphamide (Primary) ; Lapatinib (Primary) ; Trastuzumab (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 22 Aug 2021 Status changed from active, no longer recruiting to discontinued.
- 09 Jul 2019 According to ClinicalTrials.gov record, Darcy V Spicer, MD University of Southern California is the principal investigator of the study.
- 04 Jun 2019 Results (n=10) published in conjunction with the 55th Annual Meeting of the American Society of Clinical Oncology.